Scancell Holdings plc, the developer of therapeutic cancer and infectious disease vaccines based on its patented Immunobody® platform, is pleased to announce the interim results for the six month period ended 31st October 2010.
Highlights:
- Successful progression of SCIB1, Scancell's lead vaccine for melanoma, which entered clinical trials in June 2010
- Raised £2.5 million in April 2010 with new and current shareholders
- Moved from PLUS to AIM in July 2010
- Secured licensing agreements with:
- the National Institutes of Health (an agency of the United States Department of Health and Human Services); and
- Cancer Research Technology Ltd (Cancer Research UK's commercialisation and development arm)
- Entered strategic collaborations with:
- ImmuneRegen BioSciences, Inc.®; and
- immatics biotechnologies GmbH
Post-period Highlights:
- Four patients recruited to date for the clinical trials
- Approval obtained to open a fourth UK patient recruitment site and to expand the patient population in the Phase I part of the study, to include all patients with Stage III and Stage IV malignant melanoma
- Escalation of the dose and recruitment of the next group of patients in SCIB1 trial approved by the Cohort Review Committee
For further information contact:
Scancell Holdings Plc
Professor Lindy Durrant
+ 44 (0)207 245 1100
Hansard Communications
Kirsty Corcoran/Adam Reynolds
+44 (0)207 245 1100
Zeus Capital - Nominated Adviser/Joint Broker
Ross Andrews/Tom Rowley
+ 44 (0)161 831 1512
Matrix Corporate Capital LLP - Joint Broker
Robert Naylor/Stephen Waterman
View the full results